Blood-brain barrier-penetrant pharmacological strategies for neuroinflammation in Alzheimer’s disease: small molecules and engineered peptides
Abstract
Recognition of Alzheimer’s disease (AD) as a neuroinflammatory disorder, alongside amyloid-β and tau pathology, necessitates the development of innovative therapies capable of overcoming blood–brain barrier (BBB)-mediated limitations to brain drug delivery. This review discusses current efforts to develop BBB-permeable small molecules and peptide-based therapies targeting the neuroimmune modulators TREM2, the NLRP3 inflammasome, RIPK1, and the cGAS-STING signaling pathway, with consideration of the concept of the neurovascular paradox. Despite promising recent developments, the trade-off between permeability, selectivity, and cytotoxicity remains a significant issue. The current findings indicate that BBB penetration, the timing of microglial targeting, immunosuppressive effects, and neuroimmune homeostasis should be considered when seeking to modulate neuroinflammation effectively. Novel delivery systems, such as those using cell-penetrating peptide shuttles and antibody-based transport systems, may help address BBB limitations, and biomarker-guided treatment is increasingly important. Overall, this review reframes brain drug delivery not only as a function of pharmacokinetic parameters but also as part of a system integrating neurovascular physiology, neuroimmunology, and medicinal chemistry.
Related
- Discovery of a brain-penetrant CHI3L1 inhibitor as an oral modulator of neuroinflammation in Alzheimers disease
- Targeting the cGAS-STING axis in Alzheimer’s disease: neuroinflammation-centric therapeutic strategies and perspectives
- Pharmacological cGAS-STING pathway inhibition on neuroinflammation in animal models of traumatic brain injury: A systematic review and meta-analysis protocol
- Single-Cell and Spatial Transcriptomic Perspectives on Brain Ageing and Alzheimer Disease Neuroinflammation: Shared Programs and Disease-Related Reorganization
- Histone Modifications at the Intersection of Aging, Neuroinflammation and Metabolism in Alzheimer's Disease
BibTeX
@article{fatima2026bloodbrain,
title = {{Blood-brain barrier-penetrant pharmacological strategies for neuroinflammation in Alzheimer’s disease: small molecules and engineered peptides}},
author = {Faryal Fatima and Muhammad Imran Sajid and Amir Nasrolahi Shirazi and Syeda Nazish Sohaib and Fatima Abid Khan and Hafiza Ramin Shahzadi and Naglaa Salem El-Sayed and Rakesh Kumar Tiwari and Keykavous Parang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1983306},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1983306},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Blood-brain barrier-penetrant pharmacological strategies for neuroinflammation in Alzheimer’s disease: small molecules and engineered peptides
AU - Faryal Fatima
AU - Muhammad Imran Sajid
AU - Amir Nasrolahi Shirazi
AU - Syeda Nazish Sohaib
AU - Fatima Abid Khan
AU - Hafiza Ramin Shahzadi
AU - Naglaa Salem El-Sayed
AU - Rakesh Kumar Tiwari
AU - Keykavous Parang
PY - 2026
DA - 2026/11/05
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1983306
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1983306
AB - Recognition of Alzheimer’s disease (AD) as a neuroinflammatory disorder, alongside amyloid-β and tau pathology, necessitates the development of innovative therapies capable of overcoming blood–brain barrier (BBB)-mediated limitations to brain drug delivery. This review discusses current efforts to develop BBB-permeable small molecules and peptide-based therapies targeting the neuroimmune modulators TREM2, the NLRP3 inflammasome, RIPK1, and the cGAS-STING signaling pathway, with consideration of the concept of the neurovascular paradox. Despite promising recent developments, the trade-off between permeability, selectivity, and cytotoxicity remains a significant issue. The current findings indicate that BBB penetration, the timing of microglial targeting, immunosuppressive effects, and neuroimmune homeostasis should be considered when seeking to modulate neuroinflammation effectively. Novel delivery systems, such as those using cell-penetrating peptide shuttles and antibody-based transport systems, may help address BBB limitations, and biomarker-guided treatment is increasingly important. Overall, this review reframes brain drug delivery not only as a function of pharmacokinetic parameters but also as part of a system integrating neurovascular physiology, neuroimmunology, and medicinal chemistry.
SN - 1663-9812
ER -